Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

In this video, Martin Dreyling, MD, of the University of Munich in Germany, discusses results of the phase II CHRONOS-1 trial, an open-label, single-arm study evaluating the investigational PI3K inhibitor copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Dreyling highlights the mechanism of action of copanlisib, reviews response rates in the overall study population and the subset of patients with marginal zone lymphoma, and discusses the toxicity profile and future directions of study with this agent.

The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Avutometinib Combo Shows Activity, Safety for HR+/HER2- Breast Cancer

Avutometinib Combo Shows Activity, Safety for HR+/HER2- Breast Cancer

Jax DiEugenio
May 3rd 2025
Article

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Ariana Pelosci
April 28th 2025
Article

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.